Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
16 Agosto 2022 - 9:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products, and services, announces a delay in the
filing of its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022. The delay is related to the ongoing accounting
review of Biocept’s financial statements as of and for the three
months ended June 30, 2022, which ongoing review includes the
analysis of previously reported material weaknesses and matters
related to the U.S. Health Resources Services Administration (HRSA)
and its funding for reimbursement of COVID-19 testing services
performed by Biocept.
At this time, the duration of the delay in the Form 10-Q filing
cannot be reasonably estimated.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220816005413/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024